多西紫杉醇联合卡培他滨治疗乳腺癌肝转移的临床观察
|
摘要
目的探讨多西紫杉醇联合卡培他滨治疗乳腺癌肝转移的临床效果。方法选取我院2016年8月至2018年8月收治的乳腺癌肝转移患者80例,根据入院顺序分为对照组和观察组各40例。对照组采用卡培他滨治疗,观察组在此基础上采用多西紫杉醇治疗,比较两组患者的疗效、不良反应情况和出院3个月后的预后情况。结果观察组的总有效率为97.50%,明显高于对照组的82.50%(P <0.05)。观察组的不良反应发生率为62.50%,明显低于对照组的92.50%(P <0.05)。观察组的预后不良率为15.00%,明显低于对照组的35.00%(P <0.05)。结论采用多西紫杉醇联合卡培他滨治疗乳腺癌肝转移,疗效可靠,不良反应较少,且患者预后情况良好,值得临床推广应用。
Objective To explore the clinical effect of docetaxel combined with capecitabine in the treatment of liver metastasis of breast cancer. Methods 80 cases of patients with liver metastasis of breast cancer admitted to our hospital from August 2016 to August 2018 were selected and divided into control group and observation group according to the admission order, with 40 cases in each group. The control group was treated with capecitabine, while the observation group was treated with docetaxel on this basis. The curative effect,adverse reactions and prognosis 3 months after discharge were compared between the two groups. Results The total effective rate of the observation group was 97.50%, significantly higher than 82.50% of the control group(P <0.05). The incidence of adverse reactions of the observation group was 62.50%, significantly lower than 92.50% of the control group(P <0.05). The poor prognosis rate of the observation group was 15.00%, significantly lower than 35.00% of the control group(P <0.05). Conclusions Docetaxel combined with capecitabine in the treatment of liver metastasis of breast cancer has reliable efficacy, fewer adverse reactions and good prognosis, which is worthy of clinical promotion and application.
Objective To explore the clinical effect of docetaxel combined with capecitabine in the treatment of liver metastasis of breast cancer. Methods 80 cases of patients with liver metastasis of breast cancer admitted to our hospital from August 2016 to August 2018 were selected and divided into control group and observation group according to the admission order, with 40 cases in each group. The control group was treated with capecitabine, while the observation group was treated with docetaxel on this basis. The curative effect,adverse reactions and prognosis 3 months after discharge were compared between the two groups. Results The total effective rate of the observation group was 97.50%, significantly higher than 82.50% of the control group(P <0.05). The incidence of adverse reactions of the observation group was 62.50%, significantly lower than 92.50% of the control group(P <0.05). The poor prognosis rate of the observation group was 15.00%, significantly lower than 35.00% of the control group(P <0.05). Conclusions Docetaxel combined with capecitabine in the treatment of liver metastasis of breast cancer has reliable efficacy, fewer adverse reactions and good prognosis, which is worthy of clinical promotion and application.
引文
[1]杨波,杨俊兰,施伟伟,等.多西他赛联合卡培他滨或表柔比星一线治疗HER-2阴性晚期乳腺癌的临床观察[J].中华医学杂志,2013, 93(18):1397-1400.
[2]任洁.多西紫杉醇联合卡培他滨治疗转移性乳腺癌的疗效分析[J].实用癌症杂志, 2013, 28(6):649-651.
[3]许琦.乳腺癌根治术患者应用多西紫杉醇联合卡培他滨化疗及心理干预的疗效分析[J].中国生化药物杂志, 2017, 37(10):302-303.
[4]景红娟,金玉凤,叶燕萍,等.乳腺癌根治术后应用多西紫杉醇联合卡培他滨化疗及心理干预的临床观察[J].中国生化药物杂志,2017, 37(8):298-299, 301.
[5]朱柯斌.卡培他滨单药或联合方案治疗晚期乳腺癌的临床疗效观察[J].中国生化药物杂志, 2017, 37(10):98-99, 101.
[6]陈云兰,王羽丰,刘坤,等. TX与NX方案治疗乳腺癌肝转移的临床研究[J].中国妇幼保健, 2014, 29(34):5695-5697.
[2]任洁.多西紫杉醇联合卡培他滨治疗转移性乳腺癌的疗效分析[J].实用癌症杂志, 2013, 28(6):649-651.
[3]许琦.乳腺癌根治术患者应用多西紫杉醇联合卡培他滨化疗及心理干预的疗效分析[J].中国生化药物杂志, 2017, 37(10):302-303.
[4]景红娟,金玉凤,叶燕萍,等.乳腺癌根治术后应用多西紫杉醇联合卡培他滨化疗及心理干预的临床观察[J].中国生化药物杂志,2017, 37(8):298-299, 301.
[5]朱柯斌.卡培他滨单药或联合方案治疗晚期乳腺癌的临床疗效观察[J].中国生化药物杂志, 2017, 37(10):98-99, 101.
[6]陈云兰,王羽丰,刘坤,等. TX与NX方案治疗乳腺癌肝转移的临床研究[J].中国妇幼保健, 2014, 29(34):5695-5697.